Skip to main content
SpringerLink
Log in

Drug-eluting stents for cardiovascular disorders

  • Published:
Current Atherosclerosis Reports Aims and scope Submit manuscript

Abstract

Drug-eluting stents have emerged in recent years as a very promising therapy for prevention of restenosis after coronary implantation. Early randomized, clinical trials have suggested that stents eluting drugs, such as paclitaxel or sirolimus, released from polymeric and nonpolymeric coatings, are able to reduce restenosis in simple de novo lesions by more than 80% in comparison with bare metal stents. If restenosis can be indeed minimized globally by drug-eluting stents, coronary revascularization may expand to patients and lesions currently not considered for percutaneous intervention because of excessive recurrence, and may open possibilities for other stent-based endovascular treatments of atherosclerosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Mintz GS, Popma JJ, Pichard AD, et al.: Arterial remodeling after coronary angioplasty: a serial intravascular ultrasound study. Circulation 1996, 94:35–43.

    PubMed  CAS  Google Scholar 

  2. Hoffmann R, Mintz GS, Dussaillant GR, et al.: Patterns and mechanisms of in-stent restenosis. A serial intravascular ultrasound study. Circulation 1996, 94:1247–1254.

    PubMed  CAS  Google Scholar 

  3. Kastrati A, Mehilli J, Dirschinger J, et al.: Restenosis after coronary placement of various stent types. Am J Cardiol 2001, 87:34–39.

    Article  PubMed  CAS  Google Scholar 

  4. Lansky AJ, Roubin GS, O’Shaughnessy CD, et al.: Randomized comparison of GR-II stent and Palmaz-Schatz stent for elective treatment of coronary stenoses. Circulation 2000, 102:1364–1368.

    PubMed  CAS  Google Scholar 

  5. Kastrati A, Mehilli J, Dirschinger J, et al.: Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO) trial. Circulation 2001, 103:2816–2821.

    PubMed  CAS  Google Scholar 

  6. Finkelstein A, McClean D, Kar S, et al.: Local drug delivery via a coronary stent with programmable release pharmacokinetics. Circulation 2003, 107:777–784.

    Article  PubMed  Google Scholar 

  7. van der Giessen WJ, Lincoff AM, Schwartz RS, et al.: Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries. Circulation 1996, 94:1690–1697.

    PubMed  Google Scholar 

  8. Drachman DE, Edelman ER, Seifert P, et al.: Neointimal thickening after stent delivery of paclitaxel: change in composition and arrest of growth over six months. J Am Coll Cardiol 2000, 36:2325–2332.

    Article  PubMed  CAS  Google Scholar 

  9. Suzuki T, Kopia G, Hayashi S, et al.: Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model. Circulation 2001, 104:1188–1193.

    PubMed  CAS  Google Scholar 

  10. Mohacsi PJ, Tuller D, Hulliger B, et al.: Different inhibitory effects of immunosuppressive drugs on human and rat aortic smooth muscle and endothelial cell proliferation stimulated by platelet-derived growth factor or endothelial cell growth factor. J Heart Lung Transplant 1997, 16:484–492.

    PubMed  CAS  Google Scholar 

  11. Poon M, Marx SO, Gallo R, et al.: Rapamycin inhibits vascular smooth muscle cell migration. J Clin Invest 1996, 98:2277–2283.

    PubMed  CAS  Google Scholar 

  12. Marx SO, Marks AR: Bench to bedside: the development of rapamycin and its application to stent restenosis. Circulation 2001, 104:852–855.

    PubMed  CAS  Google Scholar 

  13. Gallo R, Padurean A, Jayaraman T, et al.: Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle. Circulation 1999, 99:2164–2170.

    PubMed  CAS  Google Scholar 

  14. Sousa JE, Costa MA, Abizaid A, et al.: Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries: a quantitative coronary angiography and three-dimensional intravascular ultrasound study. Circulation 2001, 103:192–195.

    PubMed  CAS  Google Scholar 

  15. Sousa JE, Costa MA, Abizaid AC, et al.: Sustained suppression of neointimal proliferation by sirolimus-eluting stents: one-year angiographic and intravascular ultrasound follow-up. Circulation 2001, 104:2007–2011.

    PubMed  CAS  Google Scholar 

  16. Sousa JE, Costa MA, Sousa AG, et al.: Two-year angiographic and intravascular ultrasound follow-up after implantation of sirolimus-eluting stents in human coronary arteries. Circulation 2003, 107:381–383.

    Article  PubMed  Google Scholar 

  17. Degertekin M, Serruys PW, Foley DP, et al.: Persistent inhibition of neointimal hyperplasia after sirolimus-eluting stent implantation: long-term (up to 2 years) clinical, angiographic, and intravascular ultrasound follow-up. Circulation 2002, 106:1610–1613.

    Article  PubMed  Google Scholar 

  18. Morice MC, Serruys PW, Sousa JE, et al.: A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002, 346:1773–1780.

    Article  PubMed  CAS  Google Scholar 

  19. Regar E, Serruys PW, Bode C, et al.: Angiographic findings of the multicenter Randomized Study With the Sirolimus-Eluting Bx Velocity Balloon-Expandable Stent (RAVEL): sirolimus-eluting stents inhibit restenosis irrespective of the vessel size. Circulation 2002, 106:1949–1956.

    Article  PubMed  CAS  Google Scholar 

  20. Serruys PW, Degertekin M, Tanabe K, et al.: Intravascular ultrasound findings in the multicenter, randomized, double-blind RAVEL (RAndomized study with the sirolimus-eluting VElocity balloon-expandable stent in the treatment of patients with de novo native coronary artery Lesions) trial. Circulation 2002, 106:798–803.

    Article  PubMed  CAS  Google Scholar 

  21. Moses JW, Leon MB, Popma JJ, et al.: SIRIUS: a US multicenter randomized, double blind study of the sirolimus-eluting stent in de novo native coronary lesions—clinical and angiographic outcomes. http://www.tctmd.com/expert-presentations/multi-slide.html?product_id=2922. Accessed September 30, 2002.

  22. Leon MB, Moses JW, Popma JJ, et al.: SIRIUS: a US multicenter randomized, double blind study of the sirolimus-eluting stent in de novo native coronary lesions - IVUS results and subset analysis. http://www.tctmd.com/expert-presentations/multi-slide.html?product_id=2902. Accessed Septebmer 30, 2002.

  23. Colombo A: The bifurcation study: an evaluation of the Cypher sirolimus-eluting stent in the treatment of patients with bifurcation lesions. http://www.tctmd.com/expert-presentations/multi-slide.html?product_id=3461. Accessed September 30, 2002.

  24. Axel DI, Kunert W, Goggelmann C, et al.: Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery [see comments]. Circulation 1997, 96:636–645.

    PubMed  CAS  Google Scholar 

  25. Sollott SJ, Cheng L, Pauly RR, et al.: Taxol inhibits neointimal smooth muscle cell accumulation after angioplasty in the rat. J Clin Invest 1995, 95:1869–1876.

    Article  PubMed  CAS  Google Scholar 

  26. Grube E, Silber S, Hauptmann KE, et al.: TAXUS I: six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation 2003, 107:38–42.

    Article  PubMed  CAS  Google Scholar 

  27. Colombo A: TAXUS-II. http://www.tctmd.com/expert-presentations/multi-slide.html?product_id=3942. Accessed February 5, 2003.

  28. Stone GW. TAXUS-IV: the pivotal US prospective, randomized trial of polymer-based slow-release taxol-eluting Express stent in de novo native coronary lesions. http://www.tctmd.com/expert-presentations/multi-slide.html?product_id=3087. Accessed Septebmer 30, 2002.

  29. Heldman AW, Cheng L, Jenkins GM, et al.: Paclitaxel stent coating inhibits neointimal hyperplasia at 4 weeks in a porcine model of coronary restenosis. Circulation 2001, 103:2289–2295.

    PubMed  CAS  Google Scholar 

  30. Park SJ, Shim WH, Ho DS, et al.: Results of a paclitaxel-eluting stent in a prospective, randomized dose-finding study. N Engl J Med 2003, in press.

  31. Gershlick AH: The ELUTES trial (European evaLUation of the pacliTaxel eluting Stent). http://www.tctmd.com/expert-presentations/multi-slide.html?product_id=1781. Accessed September 30, 2002.

  32. Grube E: Background and Clinical Outcomes with the JOMED Ceramic and PTFE Tacrolimus-Eluting Stent Platforms (PRESENT & EVIDENT). http://ww1.tctmd.com/expert-presentations/multi-slide.html?product_id=3571. Accessed Septebmer 30, 2002.

  33. Farb A, John M, Acampado E, et al.: Oral everolimus inhibits in-stent neointimal growth. Circulation 2002, 106:2379–2384.

    Article  PubMed  CAS  Google Scholar 

  34. Grube E: Animal and First Human Results with the Biosensors Everolimus-Eluting Stent (FUTURE-I) study. http://ww1.tctmd.com/expert-presentations/multi-slide.html?product_id=3504. Accessed Septebmer 30, 2002.

  35. De Scheerder I: Dexamethasone: Final STRIDE Results and Future Plans. http://www.tctmd.com/expert-presentations/multi-slide.html?product_id=3570. Accessed Septebmer 30, 2002.

  36. Serruys PW: Final ACTION Results (Actinomycin-D). http://ww1.tctmd.com/expert-presentations/multi-slide.html?product_id=3801. Accessed Septebmer 30, 2002.

  37. Chandrasekar B, Nattel S, Tanguay JF: Coronary artery endothelial protection after local delivery of 17beta- estradiol during balloon angioplasty in a porcine model: a potential new pharmacologic approach to improve endothelial function. J Am Coll Cardiol 2001, 38:1570–1576.

    Article  PubMed  CAS  Google Scholar 

  38. New G, Moses JW, Roubin GS, et al.: Estrogen-eluting, phosphorylcholine-coated stent implantation is associated with reduced neointimal formation but no delay in vascular repair in a porcine coronary model. Catheter Cardiovasc Interv 2002, 57:266–271.

    Article  PubMed  Google Scholar 

  39. New G: 17-Beta estradiol and the EASTER trial. http://www.tctmd.com/expert-presentations/multi-slide.html?product_id=3086. Accessed Septebmer 30, 2002.

  40. Mehran R, Dangas G, Abizaid AS, et al.: Angiographic patterns of in-stent restenosis: classification and implications for long-term outcome. Circulation 1999, 100:1872–1878.

    PubMed  CAS  Google Scholar 

  41. Lowe HC, Oesterle SN, Khachigian LM: Coronary in-stent restenosis: current status and future strategies. J Am Coll Cardiol 2002, 39:183–193.

    Article  PubMed  Google Scholar 

  42. Sousa JE, Costa MA, Abizaid A, et al.: Sirolimus-eluting stent for the treatment of in-stent restenosis: a quantitative coronary angiography and three-dimensional intravascular ultrasound study. Circulation 2003, 107:24–27.

    Article  PubMed  CAS  Google Scholar 

  43. Degertekin M, Regar E, Tanabe K, et al.: Sirolimus-eluting stent for treatment of complex in-stent restenosis. The first clinical experience. J Am Coll Cardiol 2003, 41:184–189.

    Article  PubMed  CAS  Google Scholar 

  44. Tanabe K, Serruys PW, Grube E, et al.: TAXUS III Trial: in-stent restenosis treated with stent-based delivery of paclitaxel incorporated in a slow-release polymer formulation. Circulation 2003, 107:559–564.

    Article  PubMed  Google Scholar 

  45. Virmani R, Kolodgie FD, Farb A, et al.: Drug eluting stents: are human and animal studies comparable? Heart 2003, 89:133–138.

    Article  PubMed  CAS  Google Scholar 

  46. Versaci F, Gaspardone A, Tomai F, et al.: Immunosuppressive Therapy for the Prevention of Restenosis after Coronary Artery Stent Implantation (IMPRESS Study). J Am Coll Cardiol 2002, 40:1935–1942.

    Article  PubMed  Google Scholar 

  47. Waksman R: Oral rapamune to inhibit restenosis: preliminary results from the ORBIT study. http://www.crtonline.org/documents//ORBIT_2_mg_data.ppt. Accessed February 7, 2003.

  48. Regar E, Sianos G, Serruys PW: Stent development and local drug delivery. Br Med Bull 2001, 59:227–248.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The Methodist DeBakey Heart Center, Baylor College of Medicine, 6535 Fannin, Room FB 1034, 77030, Houston, TX, USA

    Juan F. Granada MD, Grzegorz L. Kaluza MD, PhD & Albert Raizner MD

Authors
  1. Juan F. Granada MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Grzegorz L. Kaluza MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Albert Raizner MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Granada, J.F., Kaluza, G.L. & Raizner, A. Drug-eluting stents for cardiovascular disorders. Curr Atheroscler Rep 5, 308–316 (2003). https://doi.org/10.1007/s11883-003-0054-6

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11883-003-0054-6

Keywords

Search

Navigation